ArticleBMC ophthalmology2025
Efficacy and safety of subthreshold micropulse laser in the treatment of central serous chorioretinopathy accompanied by choroidal hemangioma: a case report.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircumscribed choroidal hemangioma (CCH) is a benign vascular hamartoma caused by congenital vascular malformation. And, central serous chorioretinopathy (CSCR) is a chorioretinal disease characterized by pachychoroid, RPE irregularities, and subretinal fluid (SRF) accumulation. Some literature has indicated a potential correlation between the occurrences of CCH and CSCR. CASE PRESENTATION: A 59-year-old man presented with blurred vision in his right eye for six months, with an unremarkable history. Multimodal imaging techniques including color fundus photography, fundus autofluorescence (FAF), B-scan ultrasonography (USG), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT), revealed the presence of CCH accompanying CSCR in the right eye. The patient received treatment with SML for CSCR, while no specific treatment was administered for CCH. The SRF was fully resolved one month after the treatment. At the 3- and 6-month follow-up, SRF resolved, and best-corrected visual acuity (BCVA) improved from 0.6 to 0.9 in the decimal format in the right eye, without notable changes in subfoveal choroidal thickness (SFCT) or the size of CCH.
conclusionThis case reported the coexistence of CCH and CSCR in the right eye, both characterized by choroidal vascular abnormalities. Further research is necessary to determine the favorable effect of SML in patients with CSCR and concurrent CCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.